ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Value-added Medicines (VAM) Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-33U18759
Home | Market Reports | Health| Pharmacy
Global Value added Medicines VAM Market Research Report 2025
BUY CHAPTERS

Global Value-added Medicines (VAM) Market Research Report 2025

Code: QYRE-Auto-33U18759
Report
January 2025
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
MS Pharma
Rovi
ELPEN
Sandoz Inc
Adamed
TIEFENBACHER GROUP
Zentiva Group
Towa International
CNX Therapeutics
Colonis
Hyloris Pharmaceuticals SA

Value-added Medicines (VAM) Market Size

The global market for Value-added Medicines (VAM) was valued at US$ 721 million in the year 2024 and is projected to reach a revised size of US$ 1450 million by 2031, growing at a CAGR of 11.3% during the forecast period.

Value-added Medicines (VAM) Market

Value-added Medicines (VAM) Market

Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.
North American market for Value-added Medicines (VAM) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Value-added Medicines (VAM) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Value-added Medicines (VAM) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Value-added Medicines (VAM) include Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Value-added Medicines (VAM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Value-added Medicines (VAM).
The Value-added Medicines (VAM) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Value-added Medicines (VAM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Value-added Medicines (VAM) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Value-added Medicines (VAM) Market Report

Report Metric Details
Report Name Value-added Medicines (VAM) Market
Accounted market size in year US$ 721 million
Forecasted market size in 2031 US$ 1450 million
CAGR 11.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, TIEFENBACHER GROUP
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Value-added Medicines (VAM) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Value-added Medicines (VAM) Market growing?

Ans: The Value-added Medicines (VAM) Market witnessing a CAGR of 11.3% during the forecast period 2025-2031.

What is the Value-added Medicines (VAM) Market size in 2031?

Ans: The Value-added Medicines (VAM) Market size in 2031 will be US$ 1450 million.

Who are the main players in the Value-added Medicines (VAM) Market report?

Ans: The main players in the Value-added Medicines (VAM) Market are Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, TIEFENBACHER GROUP

What are the Application segmentation covered in the Value-added Medicines (VAM) Market report?

Ans: The Applications covered in the Value-added Medicines (VAM) Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Value-added Medicines (VAM) Market report?

Ans: The Types covered in the Value-added Medicines (VAM) Market report are Chronic Disease Treatment Drugs, Infectious Disease Treatment Drugs, Tumor Treatment Drugs, Other

Recommended Reports

Pharmaceutical Markets

Therapeutics & Drugs

Diagnostics & Healthcare

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Market Perspective (2020-2031)
2.2 Global Value-added Medicines (VAM) Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Value-added Medicines (VAM) Historic Market Size by Region (2020-2025)
2.2.3 Value-added Medicines (VAM) Forecasted Market Size by Region (2026-2031)
2.3 Value-added Medicines (VAM) Market Dynamics
2.3.1 Value-added Medicines (VAM) Industry Trends
2.3.2 Value-added Medicines (VAM) Market Drivers
2.3.3 Value-added Medicines (VAM) Market Challenges
2.3.4 Value-added Medicines (VAM) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Players by Revenue (2020-2025)
3.1.2 Global Value-added Medicines (VAM) Revenue Market Share by Players (2020-2025)
3.2 Global Value-added Medicines (VAM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Revenue
3.4 Global Value-added Medicines (VAM) Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Revenue in 2024
3.5 Global Key Players of Value-added Medicines (VAM) Head office and Area Served
3.6 Global Key Players of Value-added Medicines (VAM), Product and Application
3.7 Global Key Players of Value-added Medicines (VAM), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Historic Market Size by Type (2020-2025)
4.2 Global Value-added Medicines (VAM) Forecasted Market Size by Type (2026-2031)
5 Value-added Medicines (VAM) Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Historic Market Size by Application (2020-2025)
5.2 Global Value-added Medicines (VAM) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Value-added Medicines (VAM) Market Size (2020-2031)
6.2 North America Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Value-added Medicines (VAM) Market Size by Country (2020-2025)
6.4 North America Value-added Medicines (VAM) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Market Size (2020-2031)
7.2 Europe Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Value-added Medicines (VAM) Market Size by Country (2020-2025)
7.4 Europe Value-added Medicines (VAM) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Market Size (2020-2031)
8.2 Asia-Pacific Value-added Medicines (VAM) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2020-2025)
8.4 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Market Size (2020-2031)
9.2 Latin America Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Value-added Medicines (VAM) Market Size by Country (2020-2025)
9.4 Latin America Value-added Medicines (VAM) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Market Size (2020-2031)
10.2 Middle East & Africa Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2020-2025)
10.4 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Zentiva Group
11.1.1 Zentiva Group Company Details
11.1.2 Zentiva Group Business Overview
11.1.3 Zentiva Group Value-added Medicines (VAM) Introduction
11.1.4 Zentiva Group Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.1.5 Zentiva Group Recent Development
11.2 MS Pharma
11.2.1 MS Pharma Company Details
11.2.2 MS Pharma Business Overview
11.2.3 MS Pharma Value-added Medicines (VAM) Introduction
11.2.4 MS Pharma Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.2.5 MS Pharma Recent Development
11.3 Towa International
11.3.1 Towa International Company Details
11.3.2 Towa International Business Overview
11.3.3 Towa International Value-added Medicines (VAM) Introduction
11.3.4 Towa International Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.3.5 Towa International Recent Development
11.4 CNX Therapeutics
11.4.1 CNX Therapeutics Company Details
11.4.2 CNX Therapeutics Business Overview
11.4.3 CNX Therapeutics Value-added Medicines (VAM) Introduction
11.4.4 CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.4.5 CNX Therapeutics Recent Development
11.5 ROVI
11.5.1 ROVI Company Details
11.5.2 ROVI Business Overview
11.5.3 ROVI Value-added Medicines (VAM) Introduction
11.5.4 ROVI Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.5.5 ROVI Recent Development
11.6 Elpen
11.6.1 Elpen Company Details
11.6.2 Elpen Business Overview
11.6.3 Elpen Value-added Medicines (VAM) Introduction
11.6.4 Elpen Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.6.5 Elpen Recent Development
11.7 Sandoz AG
11.7.1 Sandoz AG Company Details
11.7.2 Sandoz AG Business Overview
11.7.3 Sandoz AG Value-added Medicines (VAM) Introduction
11.7.4 Sandoz AG Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.7.5 Sandoz AG Recent Development
11.8 Colonis
11.8.1 Colonis Company Details
11.8.2 Colonis Business Overview
11.8.3 Colonis Value-added Medicines (VAM) Introduction
11.8.4 Colonis Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.8.5 Colonis Recent Development
11.9 Adamed
11.9.1 Adamed Company Details
11.9.2 Adamed Business Overview
11.9.3 Adamed Value-added Medicines (VAM) Introduction
11.9.4 Adamed Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.9.5 Adamed Recent Development
11.10 Hyloris Pharmaceuticals SA
11.10.1 Hyloris Pharmaceuticals SA Company Details
11.10.2 Hyloris Pharmaceuticals SA Business Overview
11.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Introduction
11.10.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.10.5 Hyloris Pharmaceuticals SA Recent Development
11.11 TIEFENBACHER GROUP
11.11.1 TIEFENBACHER GROUP Company Details
11.11.2 TIEFENBACHER GROUP Business Overview
11.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Introduction
11.11.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.11.5 TIEFENBACHER GROUP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
MS Pharma
Rovi
ELPEN
Sandoz Inc
Adamed
TIEFENBACHER GROUP
Zentiva Group
Towa International
CNX Therapeutics
Colonis
Hyloris Pharmaceuticals SA
List of Tables
 Table 1. Global Value-added Medicines (VAM) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Chronic Disease Treatment Drugs
 Table 3. Key Players of Infectious Disease Treatment Drugs
 Table 4. Key Players of Tumor Treatment Drugs
 Table 5. Key Players of Other
 Table 6. Global Value-added Medicines (VAM) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Value-added Medicines (VAM) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Value-added Medicines (VAM) Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Value-added Medicines (VAM) Market Share by Region (2020-2025)
 Table 10. Global Value-added Medicines (VAM) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Value-added Medicines (VAM) Market Share by Region (2026-2031)
 Table 12. Value-added Medicines (VAM) Market Trends
 Table 13. Value-added Medicines (VAM) Market Drivers
 Table 14. Value-added Medicines (VAM) Market Challenges
 Table 15. Value-added Medicines (VAM) Market Restraints
 Table 16. Global Value-added Medicines (VAM) Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Value-added Medicines (VAM) Market Share by Players (2020-2025)
 Table 18. Global Top Value-added Medicines (VAM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) as of 2024)
 Table 19. Ranking of Global Top Value-added Medicines (VAM) Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Value-added Medicines (VAM), Headquarters and Area Served
 Table 22. Global Key Players of Value-added Medicines (VAM), Product and Application
 Table 23. Global Key Players of Value-added Medicines (VAM), Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Value-added Medicines (VAM) Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Value-added Medicines (VAM) Revenue Market Share by Type (2020-2025)
 Table 27. Global Value-added Medicines (VAM) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Value-added Medicines (VAM) Revenue Market Share by Type (2026-2031)
 Table 29. Global Value-added Medicines (VAM) Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Value-added Medicines (VAM) Revenue Market Share by Application (2020-2025)
 Table 31. Global Value-added Medicines (VAM) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Value-added Medicines (VAM) Revenue Market Share by Application (2026-2031)
 Table 33. North America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Value-added Medicines (VAM) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Zentiva Group Company Details
 Table 49. Zentiva Group Business Overview
 Table 50. Zentiva Group Value-added Medicines (VAM) Product
 Table 51. Zentiva Group Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 52. Zentiva Group Recent Development
 Table 53. MS Pharma Company Details
 Table 54. MS Pharma Business Overview
 Table 55. MS Pharma Value-added Medicines (VAM) Product
 Table 56. MS Pharma Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 57. MS Pharma Recent Development
 Table 58. Towa International Company Details
 Table 59. Towa International Business Overview
 Table 60. Towa International Value-added Medicines (VAM) Product
 Table 61. Towa International Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 62. Towa International Recent Development
 Table 63. CNX Therapeutics Company Details
 Table 64. CNX Therapeutics Business Overview
 Table 65. CNX Therapeutics Value-added Medicines (VAM) Product
 Table 66. CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 67. CNX Therapeutics Recent Development
 Table 68. ROVI Company Details
 Table 69. ROVI Business Overview
 Table 70. ROVI Value-added Medicines (VAM) Product
 Table 71. ROVI Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 72. ROVI Recent Development
 Table 73. Elpen Company Details
 Table 74. Elpen Business Overview
 Table 75. Elpen Value-added Medicines (VAM) Product
 Table 76. Elpen Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 77. Elpen Recent Development
 Table 78. Sandoz AG Company Details
 Table 79. Sandoz AG Business Overview
 Table 80. Sandoz AG Value-added Medicines (VAM) Product
 Table 81. Sandoz AG Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 82. Sandoz AG Recent Development
 Table 83. Colonis Company Details
 Table 84. Colonis Business Overview
 Table 85. Colonis Value-added Medicines (VAM) Product
 Table 86. Colonis Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 87. Colonis Recent Development
 Table 88. Adamed Company Details
 Table 89. Adamed Business Overview
 Table 90. Adamed Value-added Medicines (VAM) Product
 Table 91. Adamed Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 92. Adamed Recent Development
 Table 93. Hyloris Pharmaceuticals SA Company Details
 Table 94. Hyloris Pharmaceuticals SA Business Overview
 Table 95. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product
 Table 96. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 97. Hyloris Pharmaceuticals SA Recent Development
 Table 98. TIEFENBACHER GROUP Company Details
 Table 99. TIEFENBACHER GROUP Business Overview
 Table 100. TIEFENBACHER GROUP Value-added Medicines (VAM) Product
 Table 101. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
 Table 102. TIEFENBACHER GROUP Recent Development
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Value-added Medicines (VAM) Picture
 Figure 2. Global Value-added Medicines (VAM) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Value-added Medicines (VAM) Market Share by Type: 2024 VS 2031
 Figure 4. Chronic Disease Treatment Drugs Features
 Figure 5. Infectious Disease Treatment Drugs Features
 Figure 6. Tumor Treatment Drugs Features
 Figure 7. Other Features
 Figure 8. Global Value-added Medicines (VAM) Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Value-added Medicines (VAM) Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Clinic Case Studies
 Figure 12. Other Case Studies
 Figure 13. Value-added Medicines (VAM) Report Years Considered
 Figure 14. Global Value-added Medicines (VAM) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Value-added Medicines (VAM) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Value-added Medicines (VAM) Market Share by Region: 2024 VS 2031
 Figure 17. Global Value-added Medicines (VAM) Market Share by Players in 2024
 Figure 18. Global Top Value-added Medicines (VAM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Revenue in 2024
 Figure 20. North America Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Value-added Medicines (VAM) Market Share by Country (2020-2031)
 Figure 22. United States Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Value-added Medicines (VAM) Market Share by Country (2020-2031)
 Figure 26. Germany Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Value-added Medicines (VAM) Market Share by Region (2020-2031)
 Figure 34. China Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Value-added Medicines (VAM) Market Share by Country (2020-2031)
 Figure 42. Mexico Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Value-added Medicines (VAM) Market Share by Country (2020-2031)
 Figure 46. Turkey Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Zentiva Group Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 50. MS Pharma Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 51. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 52. CNX Therapeutics Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 53. ROVI Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 54. Elpen Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 55. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 56. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 57. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 58. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 59. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Viral Transport Media VTM Kits Market Research Report 2025
Global Virtual Reality in Medicine and Healthcare Market Insights Forecast to 2030
Global Integrative Health or Complementary and Alternative Medicine Market Research Report 2024
Global Virtual Hospital Market Research Report 2025
Global Pharma 4 0 Market Research Report 2025
Global Pain Management Drugs Devices Market Research Report 2025
Global Virtual Medical Assistant Service Market Research Report 2025
Global Online Medical Market Research Report 2024
Global Pharma CRM Software Market Research Report 2024
Pharma and Healthcare Social Media Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Medication Management System Market Research Report 2024
Global Postoperative Pain Therapeutics Market Insights Forecast to 2030
Global Intravenous Packaging Market Research Report 2025
Global Value added Medicines VAM Development Service Market Research Report 2025
Value Based Healthcare Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Ventilator Associated Pneumonia VAP Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Medication Management Market Insights Forecast to 2030
PMMA Healthcare Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pharma and Health Care Market Research Report 2024
Global Regenerative Medicine Products Market Research Report 2025

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions